| Metric | Q3 2026 | Q3 2025 |
|---|---|---|
| Revenue | 150.7 | 149.0 |
| Gross profit | 112.9 | 100.3 |
| Profit before tax | -18.5 | -28.2 |
| Net income | -19.4 | -27.5 |
| EPS (diluted, $ a share) | $-0.15 | $-0.22 |
A dash means the filing did not report that period. Growth is not shown when either period was a loss. Figures from the filing's XBRL data.
| Revenue, year on year | +1.1% |
|---|---|
| Gross margin | 75.0% |
| Operating margin | -10.7% |
10-Q filed with the SEC, NASDAQ: TXG. Figures from the filing's XBRL data; summary written with AI assistance from the filing.
10x Genomics, Inc.: key numbers
- Share price
- $54.99Close, Nov 16
- Sector
- Industrial Applications and Services
- Industry
- Laboratory Analytical InstrumentsSIC 3826
Today's reference numbers, updated daily. Not a valuation or a recommendation.
More from 10x Genomics, Inc.
All →10x Genomics CEO Serge Saxonov Sells $1.95M of Stock
Serge Saxonov, CEO, sold 31,000 shares of 10x Genomics, Inc. at $62.90 a share, worth $1.95M in total on Nov 10, 2026. Shares held after the trade: 1,019,249 (-3.0%).
- Value
- $1.95M
- Shares
- 31,000
- Price
- $62.90
- Role
- CEO
- Holding change
- -3.0%
- Trade date
- Nov 10, 2026
10x Genomics Earnings Call: Key Takeaways
10x Genomics reported 1% revenue growth, driven by spatial consumables and the ATERA launch, while raising full-year guidance despite instrument revenue declines and anticipated gross margin compression from product mix shifts.
- Call
- Nov 5, 2026, 4:30 PM ET
10x Genomics Financial Results
10x Genomics reported Q3 2026 revenue of $150.7 million, a 1% increase year-over-year, and narrowed its net loss to $19.4 million. The company began commercial shipments of its Atera platform and raised its full-year 2026 revenue guidance to a range of $625 million to $635 million.
- Term
- Q3 2026
“The biggest highlight of the quarter was the start of commercial shipments of Atera. Enthusiasm for the platform has continued to build, and we are incredibly excited to be putting instruments in customers’ hands. We were also encouraged with the results across our broader business, driven by continued strength in consumables.”
Serge Saxonov, Co-founder and CEO of 10x Genomics
“As biology is entering a new era of AI and data maximalism, 10x is positioned incredibly well to benefit and to be the key enabler of progress going forward.”
Serge Saxonov, Co-founder and CEO of 10x Genomics
10x Genomics Executive Compensation
10x Genomics appointed Ansuman Satpathy and Joseph Gilliam to its Board of Directors as Class III directors. Both will receive compensation under the company's Non-Employee Director Compensation Policy, including an annual cash retainer of $60,000 and a one-time restricted stock unit grant valued at $400,000.